WINTON GROUP Ltd Sells 12,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN

WINTON GROUP Ltd lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 87.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,800 shares of the biopharmaceutical company’s stock after selling 12,978 shares during the quarter. WINTON GROUP Ltd’s holdings in Regeneron Pharmaceuticals were worth $1,122,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of REGN. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $26,000. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $29,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $31,000. Finally, Birchwood Financial Partners Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $781.49 on Monday. The business has a 50 day simple moving average of $754.93 and a 200 day simple moving average of $720.12. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $859.34. The stock has a market capitalization of $80.46 billion, a P/E ratio of 19.32, a P/E/G ratio of 1.53 and a beta of 0.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $12.81 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares of the company’s stock, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
• Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
• Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
• Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on REGN. HSBC lifted their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a report on Thursday. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Cantor Fitzgerald lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Citigroup upped their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Fourteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $802.18.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.